FDMT 4D Molecular Corp: ערך חשבונאי למניה

The asset value of 4D Molecular Therapeutics (FDMT) on the GURU.Markets platform, as reflected in this chart, helps assess the success of the brand that created a system for the targeted delivery of gene therapies to the eyes and heart. Business stability is ensured by an autonomous development cycle that remains independent of global crises, with the current indicator standing at 7.42. Cost optimization is achieved by outsourcing all production and testing processes to third-party contractors.

Book value per share determines the portion of net assets attributable to a single security, allowing for an assessment of the real value of capital net of all liabilities. This BVPS chart demonstrates the resilience of the financial foundation of 4D Molecular Therapeutics (FDMT), where the capitalization of intellectual property and unique gene therapy methods converts directly into growth in the company's intrinsic value.